Fosun Pharma Secures $60 Million Option for Alzheimer's Drug

MT Newswires Live

05/14

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.

The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.

If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.

Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635645367"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635645367\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635645367?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 12:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635645367","market":"nz","top_or_hot":-1,"title":"Fosun Pharma Secures $60 Million Option for Alzheimer's Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.</p><p>The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.</p><p>If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.</p><p>Shares of <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Secures $60 Million Option for Alzheimer's Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Secures $60 Million Option for Alzheimer's Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 12:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.</p><p>The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.</p><p>If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.</p><p>Shares of <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635645367","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635645367","pubTimestamp":1778733478,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical  subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0239":"医药制造","02196":"复星医药","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0188":"融资融券","BK0096":"民营医院","BK1191":"制药","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队"},"translate_title":"复星医药获得6000万美元阿尔茨海默病药物选择权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}